SCORE2 (10-year cardiovascular risk for Europe)
10-year risk of fatal and non-fatal CVD events in adults 40–69, calibrated for four European risk regions.
About this calculator
SCORE2 estimates 10-year fatal and non-fatal cardiovascular event risk in patients aged 40-69 without known CVD. Developed by the SCORE2 Working Group (Eur Heart J, 2021) in 677,684 patients from 13 European countries. Replaces original SCORE (2003). For patients >=70 use SCORE2-OP. Inputs: age, sex, systolic BP, total cholesterol, HDL, smoking. European risk regions. Low risk: Denmark, France, Israel, Luxembourg, Norway, Spain, Switzerland, Belgium. Moderate risk: Austria, Cyprus, Finland, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Malta, Portugal, San Marino, Slovenia, Sweden, UK. High risk: Czech Republic, Estonia, Hungary, Poland, Slovakia, Croatia, Turkey. Very high risk: Albania, Algeria, Armenia, Azerbaijan, Belarus, Bosnia, Bulgaria, Egypt, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lebanon, Lithuania, Moldova, Montenegro, Morocco, North Macedonia, Russia, Syria, Tunisia, Ukraine, Uzbekistan. Interpretation (ESC 2021). Ages 40-49: <2.5% – low-moderate, 2.5-7.5% – high, >=7.5% – very high. Ages 50-69: <5% – low-moderate, 5-10% – high, >=10% – very high. SCORE2-OP (70+): <7.5% – low-moderate, 7.5-15% – high, >=15% – very high. Clinical use. Stratification before statin initiation in non-CVD hypercholesterolemia. ESC 2021 recommends moderate-intensity statin at high risk, high-intensity at very high. LDL targets: <3 mmol/L at low-moderate, <2.6 at high, <1.8 at very high, <1.4 at extreme (after recurrent MI). Recalculate every 3-5 years. Limitations. Not validated for patients <40, type 1 diabetes, CKD >=stage 3, familial hypercholesterolemia, prior CVD – they are automatically very-high or extreme risk. Does not include socioeconomic factors or ethnicity (South Asian UK patients use QRISK3). ASCVD-PCE is used in the US, NICE QRISK3 in the UK, JBS3 as an alternative.
Source
Formula version: score2-working-group-2021-v1